Agios Pharmaceuticals price target raised to $34 from $32 at BofA

Group 1 - BofA raised the price target on Agios Pharmaceuticals (AGIO) to $34 from $32, maintaining a Buy rating on the shares [1] - The FDA approved mitapivat, making it the only drug approved for both transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassemia [1] - The REMS and black box warning for hepatocellular injury were in line with expectations, and BofA does not anticipate this impacting drug uptake [1]